Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
about
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Multiple myeloma in the older adult: better prospects, more challenges.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.Current approaches for the treatment of multiple myeloma.Diagnosis and therapy of multiple myeloma.Incorporating novel agents in the management of elderly myeloma patients.Initial treatment of transplant-ineligible patients in multiple myeloma.Optimal management of elderly patients with myeloma.Tretatment approach of nontransplant patients with multiple myelomaOptimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.Clinical treatment of newly diagnosed multiple myeloma.Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.New pharmacotherapy options for multiple myeloma.The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based studyA systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsAge and aging in blood disorders: multiple myeloma.Multiple myeloma in the very old: an IASIA conference report.Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms
P2860
Q27002668-005D6568-5618-4A11-8C39-0A31C3ED3FEAQ33409681-3D75E503-6D7A-4E46-81AA-271117309413Q34031129-C991A692-AFD3-4E1E-BEF5-31A0A18521E4Q35220639-173A223A-57E1-4DF3-BE24-B3C8F72B96D2Q36344688-298722AE-3AA9-436E-BFB1-F79E5EB562D8Q37615538-50F96E5C-4060-4854-A3BA-993A94A44D4EQ38087939-EC99E73E-E8E0-428E-BA81-51D58B6F044DQ38107482-5803D0ED-E76B-4EF4-B0AC-6F5CBB9C3D03Q38146974-495C3D40-BE6C-4B99-BEFA-78869E24383EQ38168891-EC1369D1-560F-4E9A-9008-A9B643F41235Q38168925-017571BC-B95C-436F-9D42-56081998CDD9Q38311072-7D678BB9-FA1F-41F0-A0AE-F9ED323F4987Q38367654-9686E93A-73B3-43A3-A884-E98BC294D7D6Q38578071-76262E7C-1011-4F1A-8131-0907F4C5A53AQ38597127-A8190136-842A-4733-8972-067AD80F41A6Q38670350-F386F819-328E-47BF-BA8C-E7EE08A1DABBQ38673764-9F108502-2C54-456D-B07F-9859BA223D7AQ38714291-97B43C27-C282-40CF-A37D-E6FB426EC3F4Q38819936-491ABAA2-1013-45F1-9E5C-637AA445FE04Q38833538-CF19852D-818E-4996-B9C3-5B728E85D2C3Q39584752-872209D8-C910-4F54-93DA-382D8B614C0DQ39836136-8F61CD40-62ED-4383-BEE8-1DB7963522E8Q42716199-9136AA0F-A4CB-4C9F-89B3-155257CAA37DQ43242121-1E07E0BC-9457-4F7B-B053-266788C9259AQ48373422-2DA140C9-CD05-420D-839C-2ADA25D3070AQ49761601-CE63F69C-E955-4191-B361-8A9C96F7A5EEQ52801394-A449F5E7-1E88-4901-B52E-9487A1FD0C8DQ52911976-D4A1B0C6-4D63-4FCB-974F-AC14924CEAE4Q58803972-6C15F97A-7B63-4C07-8E6F-C78D47AF9496
P2860
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety of thalidomide in newly ...... ents in six randomized trials.
@ast
Safety of thalidomide in newly ...... ents in six randomized trials.
@en
Safety of thalidomide in newly ...... ents in six randomized trials.
@nl
type
label
Safety of thalidomide in newly ...... ents in six randomized trials.
@ast
Safety of thalidomide in newly ...... ents in six randomized trials.
@en
Safety of thalidomide in newly ...... ents in six randomized trials.
@nl
prefLabel
Safety of thalidomide in newly ...... ents in six randomized trials.
@ast
Safety of thalidomide in newly ...... ents in six randomized trials.
@en
Safety of thalidomide in newly ...... ents in six randomized trials.
@nl
P2093
P2860
P50
P921
P1433
P1476
Safety of thalidomide in newly ...... ents in six randomized trials.
@en
P2093
Anders Waage
Brigitte Kolb
Brigitte Pégourié
Bronno van der Holt
Francesca Gay
Gunnar Juliusson
Gülsan Sucak
Henk Lokhorst
Ingemar Turesson
Jürgen Rolke
P2860
P356
10.3324/HAEMATOL.2012.067058
P577
2012-08-08T00:00:00Z